Photo from The Babak Lab/LinkedIn
Aug 20, 2024, 14:50
Key takeaways from the FDA approval of dostarlimab-gxly in endometrial cancer – The Babak Lab
The Babak Lab shared on LinkedIn:
“FDA Expands Endometrial Cancer Treatment: The FDA has approved the expanded use of dostarlimab-gxly (Jemperli) alongside chemotherapy for treating advanced or recurrent endometrial cancer.
The RUBY trial results are promising, showing significant improvements in patient outcomes, including overall survival and progression-free survival.
Key takeaways:
- Clinical Trial: Efficacy evaluated in the RUBY trial (NCT03981796) with 494 patients.
- Outcomes: Significant improvement in overall survival (OS) and progression-free survival (PFS).
- Common Adverse Reactions: Anemia, increased creatinine, peripheral neuropathy, and more.
- Recommended Dose: 500 mg every 3 weeks for 6 cycles, followed by 1,000 mg every 6 weeks.
This marks a critical advancement in the fight against endometrial cancer, offering new hope to patients. Read more on the FDA website.
Stay informed on the latest developments in cancer treatment! Image source: The Sun U.S. Edition”
Source: The Babak Lab/LinkedIn
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 22:40
Dec 21, 2024, 22:37
Dec 21, 2024, 22:26
Dec 21, 2024, 19:39
Dec 21, 2024, 19:21
Dec 21, 2024, 19:19